drugset / Trial / NCT00311740
A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)
RandomizedFactorialDouble-blindTreatment
Summary
The purpose of this study is to compare the effect of the fixed combination of valsartan+hydrochlorothiazide (HCTZ) on blood pressure reduction with valsartan and HCTZ alone and whether the combination treatments are safe and well tolerated. The study aims to establish a dose response relationship for both monotherapies and the combinations. This study is being conducted in Japan.
Timeline
- Start
- 2006-03
- Primary completion
- 2006-09
- Completion
- 2006-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydrochlorothiazide | Unknown | 6.25 mg | — |
| Subject | Hydrochlorothiazide | Unknown | 12.5 mg | — |
| Subject | Valsartan | Small molecule | 40 mg | — |
| Subject | Valsartan | Small molecule | 80 mg | — |